Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Change of AGM Date 23 October 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late clinical-stage biotechnology company dedicated to advancing innovative...
Change of AGM Date
Filed with ASX · · 1 page · English
Release
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Notification of cessation of securities - NUZ
- Updated Investor Presentation and Webinar Reminder
- FDA Type C Feedback, HEALEY trial potentially registrational
- Dr Chris Bremer commences as Neurizon CEO
- Change of Director's Interest Notice
Later from Neurizon Therapeutics
- Notice of Annual General Meeting/Proxy Form
- Appendix 4C & Quarterly Update
- Trading Halt
- Firm commitments to raise A$4.3m and announcement of SPP
- Proposed issue of securities - NUZ
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics